Literature DB >> 15373675

False reactivity in GTI Pak Plus ELISA kits due to the presence of anti-mouse antibody in patients' samples.

M F Leach1, J P Aubuchon.   

Abstract

The development of commercially available ELISA kits (GTI, Inc., Waukesha, WI) that use antigens adhered to microtiter plate wells by the use of mouse monoclonal antibodies made it possible for hospital transfusion service laboratories to test for platelet- and/or HLA-specific antibodies without reliance on reference laboratories. However, human anti-mouse antibodies (HAMAs) may cause false reactions in ELISAs. We designed a study to determine the impact of HAMAs on these ELISAs. Samples from 210 patients were evaluated from January 1995 to April 2002; 79 (38%) were found to be positive for HLA- and/or platelet-specific antibodies. Thirty (38%) of these positive samples,as well as ten negative samples that served as controls, underwent HAMA neutralization/inhibition procedures before being retested by ELISA. One (10%) of the control samples was reactive after treatment. When the samples that were positive in routine testing were treated to neutralize/inhibit HAMAs, reactivity was unchanged in 20 (67%); reactivity was eliminated in eight (27%) of the samples tested. All of the specimens that showed a reduction or elimination of their reactivity after neutralization/inhibition had an initial optical density (OD) ratio < 3.0 whereas those that remained unchanged in reactivity had an OD ratio > 7.0 (p < 0.05). Reactivity present only in the treated samples was observed in three (10%) of the positive samples tested;one was additionally reactive with HLA antigen only and two with glycoprotein Ia/IIa. The presence of HAMAs should be considered when antibodies against more than one platelet-specific glycoprotein are detected and if the optical density ratio is < 3.0.

Entities:  

Year:  2003        PMID: 15373675

Source DB:  PubMed          Journal:  Immunohematology        ISSN: 0894-203X


  3 in total

1.  Platelet antibody analysis by three different tests.

Authors:  Nazanin Sareban; Susanne Macher; Camilla Drexler; Ursula Posch; Gerhard Lanzer; Katharina Schallmoser
Journal:  J Clin Lab Anal       Date:  2014-05-05       Impact factor: 2.352

Review 2.  Challenges in the clinical utility of the serum test for HER2 ECD.

Authors:  Lian Lam; Nicholas McAndrew; Marla Yee; Ting Fu; Julia C Tchou; Hongtao Zhang
Journal:  Biochim Biophys Acta       Date:  2012-04-03

3.  IL-8 and cathepsin B as melanoma serum biomarkers.

Authors:  Hongtao Zhang; Ting Fu; Suzanne McGettigan; Suresh Kumar; Shujing Liu; David Speicher; Lynn Schuchter; Xiaowei Xu
Journal:  Int J Mol Sci       Date:  2011-02-25       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.